prikaz prve stranice dokumenta Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
Transfusion and Apheresis Science, (2022); 103582. https://doi.org/10.1016/j.transci.2022.103582
Krečak, Ivan; Skorić, Ivana; Čengić, Marina; Krečak, Filip; Skelin, Marko

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Krečak, I., Skorić, I., Čengić, M., Krečak, F. & Skelin, M. (2022). Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582

Krečak, Ivan, et al. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science, 2022. https://doi.org/10.1016/j.transci.2022.103582

Krečak, Ivan, Ivana Skorić, Marina Čengić, Filip Krečak and Marko Skelin. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science (2022). https://doi.org/10.1016/j.transci.2022.103582

Krečak, I., et al. (2022) 'Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim', Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582

Krečak I, Skorić I, Čengić M, Krečak F, Skelin M. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science [Internet]. 2022 October [cited 2024 June 06]. doi: 10.1016/j.transci.2022.103582

I. Krečak, I. Skorić, M. Čengić, F. Krečak and M. Skelin, "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim", Transfusion and Apheresis Science, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:541304. [Accessed: 06 June 2024]

Metadata
Title (english)Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
AuthorIvan Krečak
AuthorIvana Skorić
AuthorMarina Čengić
AuthorFilip Krečak
AuthorMarko Skelin
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Immune-mediated platelet transfusion refractoriness due to anti-human leukocyte antigen (HLA) antibodies can occur in approximately 9% of patients with myelodysplastic syndromes (MDS) and can lead to an increased risk of clinically relevant bleeds and treatment delays. These patients are typically managed with frequent platelet transfusions; however, HLA-matched platelet transfusions are usually available only in large blood centers. For this reason, alloimunized thrombocytopenic MDS patients are notoriously difficult to manage. Here, we present a case of a MDS patient with an immune-mediated platelet transfusion refractoriness, severe thrombocytopenia and spontaneous subarachnoid hemorhage who we successfully treated with romiplostim, a thrombopoietin receptor agonist.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusAccepted
Peer reviewPeer review - international
Publication versionPublished version
Journal titleTransfusion and Apheresis Science
Numbering103582
p-ISSN1473-0502
DOIhttps://doi.org/10.1016/j.transci.2022.103582
URN:NBNurn:nbn:hr:184:541304
Publication2022-10
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S1473050222002816
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-11-14 07:23:10